# Neuralink Summer 2025 Update: Blindsight FDA Breakthrough Designation and Scale-Up Roadmap Revealed

> clinical trial · REPORTED · 2025-07-07

At its summer 2025 public update, Neuralink confirmed FDA Breakthrough Device Designation for its Blindsight vision-restoration implant and unveiled a second-generation surgical robot, with plans to scale from current trial participants to thousands and eventually millions of users. The company also showcased live demonstrations of patients controlling robotic limbs and cursors using only neural signals.

About Neuralink: Neuralink develops fully implantable brain-computer interfaces (BCIs), including the N1 implant and Telepathy platform, to help people with paralysis, ALS, and other conditions control digital devices and robotic limbs through thought alone.

- Company: Neuralink
- Sector: medical_device
- Primary source: https://www.technology.org/2025/07/07/neuralink-telepathy-implant-summer-2025-update-key-facts/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.